The US Food and Drug Administration (FDA) has approved sotatercept (Winrevair, Merck), for the treatment of adults with pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1, ...

Second positive phase 3 trial adds to growing body of evidence for WINREVAIR, an activin signaling inhibitor therapy that targets an underlying cause of PAH RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE ...

Sotatercept reduced the relative risk of major morbidity and mortality events by 76% compared with placebo. Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S.

ZENITH was stopped early due to strong efficacy data showing reduced mortality and morbidity event risk with sotatercept. Topline interim results were announced from a phase 3 trial evaluating ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved WINREVAIR™ (sotatercept), in combination with other pulmonary ...

The U.S. Food and Drug Administration (FDA) has accepted and granted priority review for Merck & Co. Inc.’s (NYSE:MRK) new supplemental Biologics License Application (sBLA) seeking approval to update ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the ...

(RTTNews) - Merck & Co., Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Monday positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in ...

Please provide your email address to receive an email when new articles are posted on . Fewer adults diagnosed with PAH less than 1 year ago receiving add-on Winrevair vs. placebo had at least one ...

WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of ...